Business Context and Reporting Period
This Form 6-K filing by Smith & Nephew plc, dated July 12, 2024, serves as a notification and public disclosure under the EU Market Abuse Regulation. The report details transactions by Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them. The specific transaction date reported is July 5, 2024.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on insider trading activity.
| Instrument | Transaction Type | Price ($) | Total Volume (ADS) |
|---|---|---|---|
| Smith & Nephew plc SPON ADR | Purchase (Employee Stock Purchase Plan) | 21.06 | 1,771.53 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses routine purchases of American Depositary Shares (ADS) by executives as participants in the Company's Employee Stock Purchase Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory compliance document regarding specific share transactions.
Important Facts for Investors
- Transaction Nature: All reported purchases were made by executives (including CEO Deepak Nath) as part of the Company's Employee Stock Purchase Plan, not as discretionary open-market trades.
- Participants: Five individuals participated: Deepak Nath (CEO), Paul Connolly (President, Global Operations), Craig Gaffin (President, Global Orthopaedics), Mizanu Kebede (Chief Quality & Regulatory Affairs Officer), and Scott Schaffner (President, Sports Medicine).
- Transaction Details: All transactions occurred on July 5, 2024, on the New York Stock Exchange at a uniform price of $21.06 per ADS.
- Volume Breakdown: Three executives purchased 465.55 ADS each, one purchased 261.92 ADS, and one purchased 108.48 ADS.